dc.contributor.author | Kotrová, Michaela | |
dc.contributor.author | Froňková, Eva | |
dc.contributor.author | Svatoň, Michael | |
dc.contributor.author | Drandi, Daniela | |
dc.contributor.author | Schön, Felix | |
dc.contributor.author | Hoogeveen, Patricia | |
dc.contributor.author | Hancock, Jeremy | |
dc.contributor.author | Skotnicová, Aneta | |
dc.contributor.author | Schilhabel, Anke | |
dc.contributor.author | Eckert, Cornelia | |
dc.contributor.author | Clappier, Emmanuelle | |
dc.contributor.author | Cazzaniga, Gianni | |
dc.contributor.author | Schäfer, Beat W | |
dc.contributor.author | van Dongen, Jacques J M | |
dc.contributor.author | Ritgen, Matthias | |
dc.contributor.author | Pott, Christiane | |
dc.contributor.author | van der Velden, Vincent H J | |
dc.contributor.author | Trka, Jan | |
dc.contributor.author | Brüggemann, Monika | |
dc.date.accessioned | 2024-08-21T15:51:27Z | |
dc.date.available | 2024-08-21T15:51:27Z | |
dc.date.issued | 2024 | |
dc.identifier.uri | https://hdl.handle.net/20.500.14178/2583 | |
dc.description.abstract | Detection of measurable residual disease (MRD) in hematological malignancies is crucial for prognostication and treatment decisions. Real-time quantitative PCR (RQ-PCR), which targets immunoglobulin (IG) and T-cell receptor (TR) rearrangements, is deemed the gold-standard method for MRD detection in national and international clinical trials. However, this approach does have some limitations, primarily related to standard curve performance and non-specific background amplification. | en |
dc.language.iso | en | |
dc.relation.url | https://doi.org/10.1038/s41375-024-02265-z | |
dc.rights | Creative Commons Uveďte původ 4.0 International | cs |
dc.rights | Creative Commons Attribution 4.0 International | en |
dc.title | The gray area of RQ-PCR-based measurable residual disease: subdividing the "positive, below quantitative range" category | en |
dcterms.accessRights | openAccess | |
dcterms.license | https://creativecommons.org/licenses/by/4.0/legalcode | |
dc.date.updated | 2024-08-21T15:51:27Z | |
dc.subject.keyword | measurable residual disease | en |
dc.subject.keyword | Real-time quantitative PCR | en |
dc.subject.keyword | immunoglobulin | en |
dc.subject.keyword | T-cell receptor | en |
dc.identifier.eissn | 1476-5551 | |
dc.relation.fundingReference | info:eu-repo/grantAgreement/MZ0/NU/NU20-03-00284 | |
dc.relation.fundingReference | info:eu-repo/grantAgreement/UK/GAUK/GAUK318321 | |
dc.relation.fundingReference | info:eu-repo/grantAgreement/MSM//LX22NPO5102 | |
dc.date.embargoStartDate | 2024-08-21 | |
dc.type.obd | 73 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | |
dc.identifier.doi | 10.1038/s41375-024-02265-z | |
dc.identifier.utWos | 001226866300001 | |
dc.identifier.eidScopus | 2-s2.0-85193686102 | |
dc.identifier.obd | 648085 | |
dc.identifier.pubmed | 38760480 | |
dc.subject.rivPrimary | 30000::30200::30205 | |
dc.subject.rivSecondary | 30000::30200::30204 | |
dcterms.isPartOf.name | Leukemia | |
dcterms.isPartOf.issn | 0887-6924 | |
dcterms.isPartOf.journalYear | 2024 | |
dcterms.isPartOf.journalVolume | 38 | |
dcterms.isPartOf.journalIssue | 7 | |
uk.faculty.primaryId | 109 | |
uk.faculty.primaryName | 2. lékařská fakulta | cs |
uk.faculty.primaryName | Second Faculty of Medicine | en |
uk.faculty.secondaryId | 52 | |
uk.faculty.secondaryName | Fakultní nemocnice v Motole | cs |
uk.faculty.secondaryName | Motol University Hospital | en |
uk.department.primaryId | 109 | |
uk.department.primaryName | 2. lékařská fakulta | cs |
uk.department.primaryName | Second Faculty of Medicine | en |
uk.department.secondaryId | 1675 | |
uk.department.secondaryId | 100010692507 | |
uk.department.secondaryName | Klinika dětské hematologie a onkologie | cs |
uk.department.secondaryName | Klinika dětské hematologie a onkologie | en |
uk.department.secondaryName | Klinika dětské hematologie a onkologie 2. LF UK a FN Motol | cs |
uk.department.secondaryName | Department of Paediatric Haematology and Oncology, 2nd Faculty of Medicine and Motol University Hos | en |
dc.description.pageRange | 1617-1620 | |
dc.type.obdHierarchyCs | ČLÁNEK V ČASOPISU::článek v časopisu::letter to the editors | cs |
dc.type.obdHierarchyEn | JOURNAL ARTICLE::journal article::letter to the editors | en |
dc.type.obdHierarchyCode | 73::152::233 | en |
uk.displayTitle | The gray area of RQ-PCR-based measurable residual disease: subdividing the "positive, below quantitative range" category | en |